1. Home
  2. ADXN vs ACON Comparison

ADXN vs ACON Comparison

Compare ADXN & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

N/A

Current Price

$3.40

Market Cap

5.1M

Sector

Health Care

ML Signal

N/A

Logo Aclarion Inc.

ACON

Aclarion Inc.

N/A

Current Price

$1.42

Market Cap

4.5M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ADXN
ACON
Founded
2002
2008
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
4.5M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
ADXN
ACON
Price
$3.40
$1.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $7.63
AVG Volume (30 Days)
★ 773.2K
12.8K
Earning Date
11-23-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 99.82
EPS
★ N/A
N/A
Revenue
N/A
★ $75,730.00
Revenue This Year
$767.75
$44.55
Revenue Next Year
N/A
$123.97
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 65.62
52 Week Low
$2.56
$1.35
52 Week High
$10.43
$9.36

Technical Indicators

Market Signals
Indicator
ADXN
ACON
Relative Strength Index (RSI) 51.25 33.98
Support Level $2.77 N/A
Resistance Level $3.52 $3.54
Average True Range (ATR) 0.46 0.11
MACD 0.05 -0.02
Stochastic Oscillator 19.11 18.77

Price Performance

Historical Comparison
ADXN
ACON

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.

Share on Social Networks: